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ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-
TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA
Olfson M1, Marcus SC2
1Columbia University, New York, NY, USA, 2University of Pennsylvania
School of Medicine, Philadelphia, PA, USA
Non-adherence with antipsychotic medications has been impli-
cated as a proximal cause of hospital admission in the commu-
nity treatment of schizophrenia. OBJECTIVE: To estimate the
proportions of short-term inpatient admissions and hospital days
for schizophrenia in the United States that are attributable to
non-adherence with antipsychotic medications and to calculate
the corresponding total health care costs of this care.
METHODS: A series of multivariate regressions were performed
with statewide 2001–2004 California Medicaid (Medi-Cal) data
to estimate the fraction of hospital admissions and hospital days
for schizophrenia attributable to non-adherence with antipsy-
chotic medications. The 1997 Client/Patient Sample Survey was
then used to estimate the national number and length of short-
term inpatient admissions for schizophrenia. The 2002 Survey of
Mental Health Organizations was used to produce national daily
cost estimates of inpatient psychiatric care. The fraction of inpa-
tient short-term admissions attributable to non-adherence was
then applied to national estimates of the number and costs of
inpatient treatment episodes. RESULTS: Each year in the United
States, there are approximately 216,000 short-term inpatient
admissions for the treatment of schizophrenia. These admissions
include a total of approximately 2.0 million hospital days at a
total cost of approximately 1.8 billion dollars. Eliminating 
non-adherence with antipsychotic medications would lower the
number of short-term admissions by approximately 34,300
(15.6%), reduce by approximately 236,000 the number of inpa-
tient treatment days (11.7%), and save approximately 213
million dollars (11.7%) in inpatient care costs. CONLCU-
SIONS: Non-adherence with antipsychotic medications accounts
for a considerable proportion of inpatient treatment costs for
schizophrenia. Improving adherence with antipsychotic medica-
tions would likely lead to savings by reducing the frequency and
duration of inpatient treatment.
PMH20
COST OF TREATMENT OF HYPERKINETIC DISORDER IN
GERMANY
Wehmeier PM1, Rothenberger A2
1Lilly Deutschland, Bad Homburg, Germany, 2University of Göttingen,
Göttingen, Germany
OBJECTIVES: To determine the cost of treatment (CoT) associ-
ated with Hyperkinetic Disorder (HD) in Germany by age and
sex and compare it to the CoT of other childhood disorders.
METHODS: Data on the CoT of various childhood disorders
(including HD, epilepsy and asthma) were provided by the
German Federal Statistical Ofﬁce for the year 2002. The data
had been gathered by the Federal Ofﬁce from health insurance
providers. The data were broken down by diagnosis, age, sex,
and the type of resource consumed (inpatient treatment, outpa-
tient treatment, medication). The CoT of HD was then compared
to the CoT of epilepsy and asthma. RESULTS: Total treatment
costs of HD were €142 million. The highest costs (€128.8
million) were in the age group 0–15 years, where HD is most
prevalent, with 0.93% of insured girls and 3.35% of insured
boys affected. Costs also reﬂect this gender difference in preva-
lence, with €104.6 million incurred by boys and €24.2 million
incurred by girls in this age group. Treatment costs can be pri-
marily attributed to inpatient treatment (41.6%), outpatient
treatment (38.9%) and medication (5.7%). The treatment cost
of HD represents 2.2% of the total CoT in the age group 0–15
years, estimated to be €5,735 million. In this age group, other
disorders such as epilepsy (or asthma) incur treatment costs of
€199 million (€245 million). For epilepsy (or asthma), inpatient
treatment accounts for 56.1% (18.6%), outpatient treatment for
11.1% (11.1%) and medication for 26.9% (59.0%) of CoT.
CONCLUSIONS: In Germany in 2002, the CoT of HD was
€128.8 million in the age group 0–15 years. The cost of HD was
lower than the cost of other common childhood diseases and 
represents only 2.2% of the total CoT in the age group 0–15
years. Whilst inpatient treatment for HD incurs 41.6% of CoT,
medication incurs 5.7%.
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HEALTH CARE RESOURCE UTILIZATION AND COST OF
BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC
SYMPTOMS
Poston S1, Kozma C2, Meletiche DM3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Independent
Consultant, West Columbia, SC, USA, 3Ortho-McNeil Janssen
Scientiﬁc Affairs, LLC,Titusville, NJ, USA
OBJECTIVE: To compare the health care utilization and costs
between patients with a diagnosis of bipolar I disorder with 
psychotic symptoms (BPP) to patients with bipolar I disorder
without psychotic symptoms (BPO). METHODS: We conducted
a retrospective, independent group analysis using pharmacy and
medical claims from a large national managed care database.
Patients in each cohort were identiﬁed based on their ﬁrst claim
for a bipolar diagnosis during the 2003 calendar year. T-tests and
chi-square tests were used to compare variables between the two
groups. RESULTS: Of the 8221 patients who met study criteria,
7.9% of the BPP group (n = 5108) had at least one mental health-
related hospitalization, compared to 4.0% of the BPO group 
(n = 3113, p < 0.0001). Mean mental-health related hospital
costs per patient in the BPP group were $625 (SD $3326) com-
pared to $283 (SD $2223) in the BPO group (p < 0.0001).
Overall mean medication costs were $2638 (SD $3765) in the
BPP group compared to $2397 (SD$3482, p = 0.003), while
mean costs for outpatient visits (other than physician visits) were
not signiﬁcantly different (p = 0.078). Overall mean health care
costs were $10,263 (SD $19,962) in the BPP group compared to
$8,649 (SD $15,132) in the BPO group (p < 0.0001). CON-
CLUSIONS: Patients with bipolar I disorder with psychotic
symptoms had higher health care utilization and costs compared
to patients without psychotic symptoms. Research on interven-
tions targeting bipolar patients with psychotic symptoms may be
warranted.
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ANTIPSYCHOTIC POLYPHARMACY COSTS:A FIVE-STATE
MEDICAID STUDY
Valuck RJ1, Morrato EH1, Dodd SL2,Allen RR3
1University of Colorado, Denver, CO, USA, 2Ethicon, Inc, Silesia, MT,
USA, 3Peak Statistical Services, Evergreen, CO, USA
OBJECTIVES: State Medicaid programs are scrutinizing atypi-
cal antipsychotic prescribing given relatively high costs and 
use with other psychotropic medications. This study assessed
healthcare costs associated with antipsychotic polypharmacy in
ﬁve state Medicaid programs over six years. METHODS:
A retrospective cohort study using Medicaid claims data from
California, Oregon, Tennessee, Utah, and Wyoming evaluated
64,411 patients who ﬁlled an antipsychotic prescription
(1998–2003) and who were eligible 180 days prior to 365 days
after the index claim. Analysis was stratiﬁed by antipsychotic
regimen: polypharmacy (multiple antipsychotic initiation or 
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concomitant antipsychotic therapy, 60 day overlap); concomi-
tant psychotropics (30 day overlap, no polypharmacy),
polypharmacy + psychotropics; or monotherapy (no polyphar-
macy or psychotropics). ICD-9 codes (290.xx-319.xx) were used
to identify mental health diagnoses and related hospitalizations.
Total health care and drug costs were calculated for 365 days
after the index antipsychotic claim. Groups were compared using
chi-square and ANOVA tests. RESULTS: A total of 53.1%
receiving antipsychotics began and stayed on monotherapy;
39.8% received concomitant psychotropics only; 3.2%
polypharmacy only; and 3.9% polypharmacy + psychotropics.
Polypharmacy rates varied by year (p < 0.001), declining
between 1998 and 2000, then increasing through 2002. Patients
receiving polypharmacy were more likely to be male (p < 0.001),
have diagnosed schizophrenia (p < 0.001) and a mental health-
related hospitalization (p < 0.001). Median total healthcare costs
varied by therapy regimen (Mono, $3156; Psycho, $5131; Poly,
$6396; Poly + Psycho, $9342; p < 0.001). Median total drug
costs varied by therapy regimen (Mono, $1575, Psycho, $3169;
Poly, $3838; Poly + Psycho, $5833; p < 0.001). The weighted
contribution of total health care costs by regimen was: Mono,
49%; Psycho, 41%; Poly, 4%; Poly + Psycho, 6%. CONCLU-
SION: Polypharmacy rates were low during the study period,
were higher in patients with more severe mental illness, and rep-
resented a small yet signiﬁcant component of health care costs.
Future research will investigate predictors of polypharmacy and
health care costs.
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HEALTH CARE RESOURCE UTILIZATION PRE/POST
RISPERIDONE LONG-ACTING INJECTABLE TREATMENT
INITIATION IN A MANAGED CARE POPULATION
Poston S1, Locklear JC2, Kozma C3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil
Janssen Scientiﬁc Affairs, LLC,Titusville, NJ, USA, 3Independent
Consultant, West Columbia, SC, USA
OBJECTIVE: To assess healthcare utilization and associated cost
in schizophrenia and schizoaffective patients pre/post risperidone
long-acting injectable (RLAI) treatment initiation. METHODS:
A retrospective evaluation utilized pharmacy and medical claims
to assess healthcare resource utilization and costs of adult schiz-
ophrenia patients from a mental health subset of managed care
data. Inclusion criteria required a diagnosis of schizophrenia or
schizoaffective disorder, at least one claim for RLAI between
December 2003 and June 2004, and six months of continuous
eligibility criteria pre and post the initial RLAI claim. The initial
RLAI claim served as the index date. The observation period was
12 months, including 6-month pre and 6-month post RLAI treat-
ment initiation where patients served as their own control.
Healthcare utilization outcome variables included hospitaliza-
tions, emergency room use, outpatient visits, and medications.
Costs represent the amount paid by the health plan for services.
RESULTS: Results are available for the 26 patients meeting
inclusion criteria. Mean patient age was 37 ± 13.4 years, and
53.8% of the population were male. The mean number hospi-
talizations per patient decreased from 0.77 in the pre-period to
0.35 in the post-period (p = 0.06). The costs for hospitalizations
decreased from $14,456 ± $28,745 in the pre-period to $4,201
± $13,876 (p < 0.05). Outpatient utilization remained statisti-
cally unchanged between the pre and post period, while the costs
for psychoactive medications signiﬁcantly increased in the post
period. Total healthcare costs trended downward, from an
average of $22,650 ± $30,856 in the pre-period to $15,182 ±
$18,209 in the post-period (p = 0.09). Sensitivity analyses con-
ducted around the index date resulted in a statistically signiﬁcant
decrease in total health care costs in the post period. CON-
CLUSIONS: In this US managed care patient population, hospi-
talization costs signiﬁcantly decreased post (RLAI) treatment
initiation. Further studies with larger sample sizes are needed to
conﬁrm ﬁndings.
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INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS:
EFFECTS ON THE TREATMENT FOR SCHIZOPHRENIA IN A
MEDI-CAL POPULATION
Vicki L Biagi, MPH1, Lee Crandall, Ph.D.1, Jeffrey S. McCombs, Ph.D.2
1University of Miami, Florida, 2University of Southern California
OBJECTIVES: Evaluate the effects of open access to atypical
antipsychotics on patients with schizophrenia recently dis-
charged from a hospital. METHODS: Retrospective database
analysis of episodes of antipsychotic drug therapy using data
from the California Medicaid (Medi-Cal) program. Episodes ini-
tiated between January 1994 and August 2000 were included in
this analysis. Open access was implemented in October 1997.
Selection criteria include a schizophrenia diagnosis; 6 months of
data prior to and 12 months of data post episode start and insti-
tutionalization in an acute or psychiatric hospital within the
prior 30 days. The ﬁnal data set consisted of 3290 post-
discharge episodes of treatment. Multivariate logistic regression
models were estimated for the likelihood of using an atypical
antipsychotics post-discharge and the likelihood of re-
institutionalization in an acute or psychiatric hospital or nursing
home. RESULTS: Open access increased the use of atypical
antipsychotics by discharged patients by 8-fold (CI:
6.154–10.636). Moreover, use of atypical antipsychotics
increased disproportionately for blacks (OR 0.514 vs. 0.914)
and for other minorities (OR 0.933 vs. 1.194) relative to white
patients. While access to atypical antipsychotics improved for
black patients with open access, their use rates were still not
equal to white patients. However, the estimated changes in access
for other minority patients after implementation of open access
did achieve statistical signiﬁcance such that there was no statis-
tically signiﬁcant difference compared to whites in the open
access period. But, more importantly, open access decreased the
risk of re-institutionalization in an acute or psychiatric hospital
(OR 0.67, CI: 0.557–0.816) and long term care (LTC) facilities
(OR 0.67, CI: 0.493–0.916). CONCLUSIONS: Granting open
access to innovative drugs reduced racial disparities in the use of
atypical antipsychotics for minority patients upon hospital dis-
charge. Open access reduced the risk of re-institutionalization in
acute hospitals and long term care facilities.
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LEARNING FROM NICE TECHNOLOGY ASSESSMENTS:
A CASE STUDY OF ITS RECENT APPRAISAL OF ADHD
TREATMENT STRATEGIES
Schlander M
Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany
Health care policy makers need valid, objective, unbiased, and
methodologically sound technology assessments. Frequently the
approach established by the National Institute for Health and
Clinical Excellence (NICE) is regarded as a reference standard
internationally. OBJECTIVE: To use the recent appraisal of
attention-deﬁcit/hyperactivity disorder (ADHD) treatments as a
case study to explore whether NICE technology appraisals meet
quality expectations when addressing complex clinical problems.
METHOD: Tracking the ADHD treatment appraisal by NICE
